Loading asset research
Vera Therapeutics Inc. Class A Common Stock
VERANasdaq · USD · StocksQuote as of · Exchange session not verified$35.05
+4.32%
Today
VERA
Loading 1D prices…
Market cap
$2.5B
Volume
3.8M
52w high
$56.0552w low
$22.72Company profile
Vera Therapeutics Inc. Class A Common Stock
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with immunological diseases. The company offers atacicept, a fully humanized TACI-Fc fusion protein that binds B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL), which is self-administered at home as a subcutaneous injection being evaluated for the treatment of immunoglobulin A nephropathy (IgAN) and other autoimmune kidney diseases. It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections that has completed phase 2 clinical trial; and VT-109, a novel BAFF/APRIL dual-inhibitor B cell maturation antigen (BCMA) molecule to treat B cell mediated autoimmune diseases. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.
Sector
Health Care
Industry
Pharmaceutical Preparations
Exchange
Nasdaq
Display currency
USD
Location
Brisbane, CA, United States
Employees
361
Fiscal year end
1231
CIK
1831828
Session & valuation
Open$33.91
Previous close$33.60
Day high$35.29
Day low$33.75
30-day avg. volume2.1M
Outstanding shares72.1M
Diluted EPS-$4.66
Latest annual period
P/E (trailing)-7.52
P/E (forward)-8.02
Price / book6.18
Beta0.95
Dividend yield—
Deterministic peer set
Companies with SEC SIC 2834
Exact regulatory industry matches, ranked by nearest market capitalization.
| Company | Market cap | Revenue | Net margin | Diluted EPS | Today | Consensus |
|---|---|---|---|---|---|---|
| MLYSMineralys Therapeutics Inc. Common Stock | $2.5B | $0.00 | — | -$2.29 | -3.72% | Buy |
| PGENPrecigen Inc. Common Stock | $2.5B | $9.7M | -2587.77% | -$1.37 | +2.54% | Buy |
| NRIXNurix Therapeutics Inc. Common stock | $2.6B | $84M | -314.90% | -$3.05 | -2.71% | Buy |
| SUPNSupernus Pharmaceuticals Inc. Common Stock | $2.4B | $719M | -5.37% | -$0.68 | -0.10% | Buy |
| MRVIMaravai LifeSciences Holdings Inc. Class A Common Stock | $2.4B | $185.7M | -70.42% | -$0.90 | -3.12% | Buy |